RepliCel Life Sciences Inc., a company which specializes in developing cell therapies for orthopedic and aesthetic conditions, received a U.S. patent on April 25, 2017 for its new, multi-needle dermal injection devices. These devices fit as a solution to soaring need for dermal injection technologies capable of bringing high levels of control and precision to any elements injected into the skin.
The patent received from the U.S. Patent and Trademark Office (USPTO) covers technologies designed to allow both repeatable consistency and unparalleled control of product deposition and needle action. The patent also includes the component developed to numb the skin before using injection, with the intention to reduce, if not eliminate, the requirement for local anesthetic prior to aesthetic injection processes.
RepliCel Inches Closer to Launch of RCI-02 with Patent Issued
The first device being designed under the umbrella of this patent is RCI-02, which will be useful in injecting soft tissue fillers, including hyaluronic acid (“HA”). The device is also being designed for injecting RCS-01 skin rejuvenation and RCH-01 hair restoration products. It is expected to be optimized for other injectable such as biologics, drugs, fat grafts, and biologics.
With this patent, the company’s property portfolio has reached a new milestone. The portfolio already included two European patents for RCI-02. Company officials believe that this multi-needle device will be able to deliver unprecedented reproducibility, reliability, and programmability of 3D skin injections, making desired outcomes a much easier thing to attain for both clinicians and less-experienced injection specialists. The prototypes are estimated to get ready by the third quarter of 2017 for initial usability and functional testing by engineers and end users.
Anyone operating in the medical equipment and technology sector should have an insight into this recently discovered ‘mother of all acquisitions.’ C.R. Bard, a medical device behemoth, has been sold to fellow giant company Becton, Dickinson and Company. Bard has agreed to function under the leadership of Becton Dickinson in a titanic deal of US$24.0 bn or thereabouts.
Companies that supply to hospitals and healthcare centers have attracted eyeballs after the mega deal. The eye-watering acquisition deal kicked Bard’s shares up to almost 20.0% on Monday. Bard will receive an approximately over 25.0% than its share close price of April 21, 2017. This means that Becton Dickinson will bless Bard with a handsome US$317.0 per share, which could be in cash and shares.
Medical Supply and Healthcare Sectors on Merger and Acquisition Spree
Pricing pressure and the need to expand product portfolio are the top reasons that the medical devices sector is witnessing a series of mergers and acquisitions. However, Bard has a different, rather positive, perspective this its acquisition by Becton Dickinson. It will look to leverage the superintendence of Becton Dickinson in infection prevention and medication management to offer worthwhile advantages to patients and customers.
A couple of years back, CareFusion Corp was acquired by Becton Dickinson for exactly half the price of the Becton Dickinson-Bard deal, whereas Abbott Laboratories had acquired St. Jude Medical, Inc. for a billion more than the mega deal price in January 2017.
The scenario of mergers and acquisitions is not merely followed by medical equipment companies, hospitals are also part of the strategy as they share office with larger centralized operations and health systems.
Millions of Americans are prey to the newest bad habit that seems to be worse than smoking. Long hours of sitting and sedentary lifestyles have led to a wide range of health issues in the U.S. Desk jobs, recreational activities such as watching TV, playing video games, and long hours of sitting is proving to be a fatal pastime. Thankfully, smoking is down to 17% at the moment from 42% in 1965 due to laws and regulations preventing smokers from lighting up at restaurants and other public places. However, the new habit of sitting is estimated to cause greater losses in the coming years.
Lack of Movement Gives Rise to a Range of Dangerous Diseases
Changing lifestyles that are best described by negligible walking are likely to cause a new range of preventable diseases amongst Americans. The biggest challenge created by doing nothing but sitting – as the commute is through vehicles, working is at desks, east and drinking is at tables, and then sleeping in bed – is obesity. The National Institutes of Health stated that obesity and being overweight leads to 300,000 deaths every year. The Centers for Disease Control and Prevention reported that though the deaths due to lung cancer have dropped by 2%, while the issue of obesity seems to be on the rise. By the end of 2015, about 20% of the adults were suffering from obesity.
In the wake of the aforementioned lifestyle changes, sedentary lifestyles, and subsequent obesity, the world is likely to see a rise in the cases of cardiovascular diseases, diabetes, and cancer among others. Prolonged sitting is also expected to cause venous insufficiency, which causes blood to pool in legs. A lot of body’s functioning relies on the movement it receives. Thus, it is extremely important for people to keep walking or to incorporate exercise in daily routine in order to achieve healthier bodies that will function better over a long period of time.
Geko, a neuromuscular electro-stimulation medical device, much like a watch has become a game changer for all those people lying on hospital beds with ankle fractures, waiting for the swelling to reduce so that doctors can perform a surgery. Geko sticks to the plaster cast, above a patient’s leg and causes muscles to contract, helping in reducing the swelling by increasing the blood circulation.
Sky Medical Technology Wins Medilink North West Healthcare Business Award
Although Geko is commonly used for the prevention of deep vein thrombosis, experts at Middlesbrough’s James Cook University Hospital have recognized the potential of this device to help patients waiting endlessly for swelling to reduce in order to be operated. This not only saves time but also expenses of lying on hospital beds. The experts at James Cook initially experimented by teaming up with Sky Medical Technology and studied 20 patients, who were happy to wear the Geko and experience a reduction in swelling within 24 hours. Medilink North West Healthcare Business Award has been awarded to Sky Medical Technology for their fruitful partnership working with the NHS.
Detailed Research on Geko could Help Treatment of Future Patients
Paul Baker, an orthopedic surgeon is planning on carrying out an extensive research on this device to be able to benefit many future patients. Geko has brought relief to many patients with ankle fractures by eliminating the need to stay in hospitals for weeks, getting frustrated, and also losing muscle mass. Senior sister Stacey Brown stated that the results have been remarkable and patients have responded to this device quite well.